DexCom (DXCM)
(Delayed Data from NSDQ)
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$69.00 USD
-0.70 (-1.00%)
Updated Nov 5, 2024 04:00 PM ET
After-Market: $68.91 -0.09 (-0.13%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth A Momentum B VGM
Zacks News
Is DexCom (DXCM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DexCom (DXCM) and Exscientia PLC Sponsored ADR (EXAI) have performed compared to their sector so far this year.
Boston Scientific (BSX) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment.
Myriad Genetics' (MYGN) New Partnerships Aid Amid FX Woes
by Zacks Equity Research
Myriad Genetics (MYGN) continues to record strong revenue growth from companion diagnostics, including significant revenue share from its proprietary myChoiceCDx test.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
by Zacks Equity Research
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Reasons to Retain Baxter International (BAX) in Your Portfolio
by Zacks Equity Research
Baxter International's (BAX) robust growth across all geographies, along with transformational initiatives, boosts confidence. However, pandemic-related disruption continues to hurt sales.
Medtronic (MDT) Expands AI-Driven Care With New Partnership
by Zacks Equity Research
Medtronic's (MDT) expanded collaboration with Cosmo Pharmaceuticals is a strategic step forward in its quest to use AI to improve patient care.
Here's Why You Should Retain Exact Sciences (EXAS) Stock Now
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on strong Cologuard adoption and raised guidance.
QIAGEN's (QGEN) Strategic Alliances Aid Amid Macro Woes
by Zacks Equity Research
QIAGEN (QGEN) aims to expand the NGS platform by rapidly scaling up the new Enterprise Genomics Services.
Terumo (TRUMY) Launches AZUR HydroPack in Embolotherapy Space
by Zacks Equity Research
Terumo's (TRUMY) coil system boasts a soft, universal-shaped platinum and hydrogel composition, which sets it apart in the peripheral coil market.
Integer Holdings (ITGR) Hits 52-Week High: What's Aiding It?
by Zacks Equity Research
Investors are optimistic about Integer Holdings' (ITGR) solid foothold in the broader MedTech space.
Integer Holdings Corporation (ITGR) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Integer (ITGR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Charles River (CRL) Expands 3D In Vitro Services Via New Deal
by Zacks Equity Research
Charles River (CRL) finalizes agreement with service-based biotechnology company, CELLphenomics.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from strategic partnerships and strength in the Distribution Solutions segment.
Masimo's (MASI) ORi Favored by Study for PaO2 Information
by Zacks Equity Research
Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.
Here's Why You Should Retain Surmodics (SRDX) Stock for Now
by Zacks Equity Research
Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.
Here's Why Investors Should Retain ResMed (RMD) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about ResMed (RMD) due to the sustained growth in the SaaS business.
Thermo Fisher (TMO) Launches New Solutions for Clinical Labs
by Zacks Equity Research
Thermo Fisher (TMO) introduces the KingFisher Apex Dx system and Applied Biosystems MagMAX Dx Isolation Kit to improve preanalytical workflows for clinical laboratories.
Reasons to Add Cardinal Health (CAH) to Your Portfolio Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from a solid pharmaceutical segment and a diversified product portfolio. However, the rising cost of products is a concern.
Edwards Lifesciences (EW) Forwards Growth Strategy and Outlook
by Zacks Equity Research
Edwards Lifesciences' (EW) TAVR remains strong, driven by greater awareness, patient activation and advances in new technologies such as RESILIA.
Why You Should Retain Merit Medical (MMSI) Stock for Now
by Zacks Equity Research
Merit Medical's (MMSI) strong product portfolio raises optimism about the stock.
McKesson (MCK) Announces Availability of FDA-Approved Drug
by Zacks Equity Research
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for desmoid tumors.
Illumina (ILMN) Expands Globally Despite Macroeconomic Woes
by Zacks Equity Research
The NovaSeq X launch strengthens Illumina's (ILMN) competitive position in high-throughput sequencing.
Walgreens' (WBA) AllianceRx Pharmacy Will Now Distribute XDEMVY
by Zacks Equity Research
Walgreens' (WBA) subsidiary, AllianceRx Walgreens Pharmacy, is one of the four specialty pharmacies selected to distribute XDEMVY.
AMN Healthcare's (AMN) New Tie-Up to Boost Patient Outcome
by Zacks Equity Research
AMN Healthcare's (AMN) collaboration is likely to bolster its portfolio of products and simplify the language procurement process for customers.
BrainsWay (BWAY) Strengthens South Korean Foothold With Deep TMS
by Zacks Equity Research
BrainsWay's (BWAY) Deep TMS targets affected brain structures with a magnetic field, stimulating crucial neural networks.